Paola Montserrat Zaragoza Ojeda

Dr. Paola Montserrat Zaragoza Ojeda

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Toxicology Letters
Verified
Journal Article
Closed access
POPaola Montserrat Zaragoza Ojeda
Paola Montserrat Zaragoza Ojeda
PEPilar Eguía-Aguilar
Pilar Eguía-Aguilar
Mario Perezpeña-DiazcontiMario Perezpeña-Diazconti
Mario Perezpeña-Diazconti
FAFrancisco Arenas-Huertero
Francisco Arenas-Huertero

Verified
Journal Article
Open access
PDF file
DLDaniel García López
Daniel García López
POPaola Montserrat Zaragoza Ojeda
Paola Montserrat Zaragoza Ojeda
PEPilar Eguía
Pilar Eguía
FAFrancisco Arenas-Huertero
Francisco Arenas-Huertero
The endoplasmic reticulum maintains proteostasis, which can be disrupted by oxidative stress, nutrient deprivation, hypoxia, lack of ATP, and toxicity caused by xenobiotic compounds, all of which can result in the accumulation of misfolded proteins. These stressors activate the unfolded protein response (UPR), which aims to restore proteostasis and avoid cell death. However, endoplasmic response-associated degradation (ERAD) is sometimes triggered to degrade the misfolded and unassembled proteins instead. If stress persists, cells activate three sensors: PERK, IRE-1, and ATF6. Glioma cells can use these sensors to remain unresponsive to chemotherapeutic treatments. In such cases, the activation of ATF4 via PERK and some proteins via IRE-1 can promote several types of cell death. The search for new antitumor compounds that can successfully and directly induce an endoplasmic reticulum stress response ranges from ligands to oxygen-dependent metabolic pathways in the cell capable of activating cell death pathways. Herein, we discuss the importance of the ER stress mechanism in glioma and likely therapeutic targets within the UPR pathway, as well as chemicals, pharmaceutical compounds, and natural derivatives of potential use against gliomas.

15 June 2024 in Chemosphere
Verified
Journal Article
Closed access
JPJosefina Poblano-Bata
Josefina Poblano-Bata
POPaola Montserrat Zaragoza Ojeda
Paola Montserrat Zaragoza Ojeda
ARAndrea De Vizcaya Ruiz
Andrea De Vizcaya Ruiz
FAFrancisco Arenas-Huertero
Francisco Arenas-Huertero
OAOmar Amador-Muñoz
Omar Amador-Muñoz

2 June 2023 in Natural Product Research
Verified
Journal Article
Closed access
MEMaría Mirian Estévez-Carmona
María Mirian Estévez-Carmona
MRM. Teresa Ramírez-Apan
M. Teresa Ramírez-Apan
POPaola Montserrat Zaragoza Ojeda
Paola Montserrat Zaragoza Ojeda
AVAnita Vega-Miranda
Anita Vega-Miranda
FAFrancisco Arenas-Huertero
Francisco Arenas-Huertero
MOMarco A. Obregón-Mendoza
Marco A. Obregón-Mendoza
The new phenyl glycine derivative of perezone was obtained in a single reaction step in ca. 80% yield which showed remarkable cytotoxic activity against the astrocytoma U-251 cell line. After 24 h of exposure, both perezone (IC50 = 6.83 ± 1.64 µM) and its phenyl glycine derivative (2.60 ± 1.69 µM) showed cytotoxic effect on U-251 cells but were five times less cytotoxic on the non-tumoral SVGp12 cell line (IC50 = 28.54 ± 1.59 and 31.87 ± 1.54 µM respectively). Both compounds induced cellular morphological changes (pyknosis or cytoplasmic vacuolization) and increased the expression of caspases 3, 8, and 9 genes related to apoptosis. In the acute toxicity study, phenyl glycine perezone (DL50 = 2000 mg/Kg) demonstrated to be less toxic than perezone (DL50 = 500 mg/Kg). Phenylglycine-perezone can envisage a beneficial therapeutic potential.